Research article

Reyadh Jassim Abbas^1,*,May Al- Sabbagh¹, Dr Hassan Mohammed Abbas Altemmi², Dr Monewer³


Affiliation:-
¹Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
²Ph.D Clinical Pharmacy, Medical City Baghdad, Baghdad Iraq, 3MSC Oncology Medical City Baghdad, Iraq

The name of the department(s) and institution(s) to which the work should be attributed:
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi

Address reprint requests to
Reyadh Jassim Abbas
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi 

Article citation:
Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. The possible protective effect of melatonin in Iraqi breast cancer patients taking chemotherapy. J Pharm Biomed Sci. 2014; 04(11):1001-1006. Available at www.jpbms.info

ABSTRACT
Breast cancer is the most common cancer that lead to death in the world. The most common type of breast cancer is ductal carcinoma. Chemotherapy that used in the treatment of breast cancer is associated with adverse effects like cardio toxicity, especially with doxorubicin use, due to increase free radical formation like reactive oxygen species. To evaluate the protective effect of melatonin in Iraq breast cancer taking chemotherapy, 40 volunteers, 10 normal subjects served as control, 30 volunteers were divided into two groups randomly first 10 patient named group A taking only chemotherapy without melatonin. The second 20 patient named group B taking melatonin + chemotherapy. In the  current study, we measured serum malondialdehyde (MDA), liver function test (ALT, AST and TSB) and cardiac enzyme (CPK and LDH). The results showed that chemo therapy increase serum MDA, AIT, AST, CPK, LDH and reduction in serum TSB. Patients who taking extra supplement with melatonin (group B) showed normalized of these biochemical parameters. Melatonin has a role in protecting against toxicity that produced by chemotherapy.


KEYWORDS: Breast cancer; Chemotherapy; melatonin.

REFERENCES
1.American cancer society . Breast cancer . Fact and Figure 2009. American cancer society, Atlanta, GA2009.
2.Iraq cancer registry, 2010,p28.
3.Wood, WC  et at. Malignant tumor of breast in ;devitant,Hellman editor.Cancer principle and practice of oncology 7th edition , Philadelphia Pa. Lippincott william and Wilkins, pp77-1415.
4.Chu, E et al . Cancer chemotherapy.In; Katzung BG,editor. Basic and clinical pharmacology, 9th edition . Mc Graw-Hill, pp: 898-930.
5.Stefulj J et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243–247.
6.Ackermann K et al. Melatonin synthesis in the human pineal gland .BMC neuroscience. 2007; 8supp1:p2.
7.Pieri C. Melatonin peroxyl radical scavenger more effective than vit. E Life sci. 55(15): PL 271-6.
8.Reitman and frankel. As cited by Bio Merieux kit (france). Am J Clin Path.1957;28:56 .
9.Tietz N.W. text book of clinical chemistry 3rd ed. (1999):1133-1137.
10.Buege, JA, Austa SD. Method enzymol. 1978;51:302-310.
11.Sharhar S. et al. Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: A case-control study. Asian Pac. J. Cancer Prev. 2008;9:343–349.
12.Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17-29.
13.A.Nath et al. Elevated lipid peroxidation in breast cancer patients, Journal of pharmacy and biological sciences (JPBS),2001;9(4):17-21.
14.Shaoyu Zhou,et al. Doxorubicin–induce persistent oxidative stress to cardiac myocytes.2001;121:(3):151-157.
15.Ganiyu Oboh et al . Cyclophosphamide- induced oxidative stress in brain. Experimental and Toxicologic Pathology.2014;66(8):351-406.
16.Satoshi Numazawa et al. Possible Involvement of Oxidative Stress in 5-Fluorouracil-Mediated myelosuppression in mice. Basic & Clinical Pharmacology & Toxicology.2011;108(1):40–45.
17.Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNAdamage in the rat kidney. Toxicology.1999;139:81–91.
18.Bateman JR, et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer. 1971;28:907-913.6
19.Paul D. King et al.Hepatotoxicity of Chemotherapy, The Oncologist.2001;6:162-176.p163.
20.Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU). Biochem Pharmacol 1983;32:1383-1388.
21.Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chemico-Biological Interactions. 2003;146:201-210.
22.Dr. Mustafa Ghazi Alabbassi. Melatonin Ameliorates Hepatic Damage Induced by Cyclophosphamide in rat.
23.Bahir Abdul Razzaq Mshemish et al . Effect of Silymarin against CAF protocol Hepatotoxicity, AJPS, 2011, Vol. 9, No.1.
24.Khalid A Al-Khazragi FRCP. Studying the Effect of Silymarin Against Hepatotoxicity Induced by CAF Protocol in Breast Cancer Women. Iraqi Medical Journal , Volume 56, Number 2, December 2010, ISSN 0304-4564.
25.Kamal Adel Amin,et al . Impact of Breast Cancer and Combination Chemotherapy on Oxidative Stress, Hepatic and Cardiac Markers, Sep 2012:15(3);306-312.
26.Ayça Bilgino?lu, M.D et al. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Arch Turk Soc Cardiol 2014; 42(3):265-273.
27.Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. http://www.nlm.nih.gov. Drug Saf. 2000 Apr;22(4):263-170.


Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.


Copyright © 2014 Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.